Bladder Cancer

Oncology·MeSH: Urinary Bladder Neoplasms

Prevalence

61.0 / 100K

Incidence

18.0 / 100K/yr

47 drugs in development·23 companies·58 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
zusduri	UroGen Pharma Ltd. (URGN)

Phase 3(25)

Drug	Company
bacillus calmette guerin	GH Research PLC (GHRS)
bacillus calmette-guerin	ASTRAZENECA PLC (AZN)
bcg	ASTRAZENECA PLC (AZN)
bcg vesiculture	GH Research PLC (GHRS)
bcg+n-803. )	ImmunityBio, Inc. (IBRX)
cetrelimab	GH Research PLC (GHRS)
cretostimogene	CG Oncology, Inc. (CGON)
cretostimogene grenadenorepvec	CG Oncology, Inc. (CGON)
enfortumab vedotin	ASTRAZENECA PLC (AZN)
Enfortumab Vedotin	Merck & Co., Inc. (MRK)
MK-3120	Merck & Co., Inc. (MRK)
nadofaragene firadenovec	VERTEX PHARMACEUTICALS INC / MA (VRTX)
Nadofaragene Firadenovec	Merus N.V. (MRUS)
Nadofaragene Firadenovec	Valneva SE (VALN)
Rescue medications for chemotherapy	Merck & Co., Inc. (MRK)
Rescue medications for sacituzumab tirumotecan	Merck & Co., Inc. (MRK)
Supportive care measures	Merck & Co., Inc. (MRK)
tar-200	GH Research PLC (GHRS)
tara-002	Protara Therapeutics, Inc. (TARA)
ugn-102	UroGen Pharma Ltd. (URGN)
ugn-103	UroGen Pharma Ltd. (URGN)
ugn-201	UroGen Pharma Ltd. (URGN)
ugn-301	UroGen Pharma Ltd. (URGN)
Vinflunine	Merus N.V. (MRUS)
Vinflunine	Merck & Co., Inc. (MRK)

Phase 2(8)

Drug	Company
ae37	NUGENEREX IMMUNO-ONCOLOGY, INC. (NGIO)
lp-50	LIPELLA PHARMACEUTICALS INC. (LIPO)
N-803 and BCG	ImmunityBio, Inc. (IBRX)
oncolytic adenovirus expressing gmcsf	CG Oncology, Inc. (CGON)
Vinblastine	Janux Therapeutics, Inc. (JANX)
Vinblastine	ARS Pharmaceuticals, Inc. (SPRY)
Vinblastine	Myovant Sciences Ltd. (MYOV)
Vinblastine	Royalty Pharma plc (RPRX)

Phase 1(7)

Drug	Company
AU-011	Aura Biosciences, Inc. (AURA)
fpi-1966	Fusion Pharmaceuticals Inc. (FUSN)
HMBD-001	KYNTRA BIO INC. (KYNB)
N-803	ImmunityBio, Inc. (IBRX)
neo-pv-01	Neon Therapeutics, Inc. (NTGN)
prn1371	Principia Biopharma Inc. (PRNB)
romidepsin	GH Research PLC (GHRS)

Preclinical(2)

Drug	Company
personalized cancer vaccine	GreenLight Biosciences Holdings, PBC (GRNA)
uio-524	Transcode Therapeutics, Inc. (RNAZ)

Unknown(1)

Drug	Company
ADSTILADRIN	CG Oncology, Inc. (CGON)

Phase 1/Phase 2(2)

Drug	Company
BCG	ImmunityBio, Inc. (IBRX)
bcg + n-803	ImmunityBio, Inc. (IBRX)

Phase 4(1)

Drug	Company
HMBD-001 and enzalutamide	KYNTRA BIO INC. (KYNB)

BioSniper tracks 47 drugs in development for Bladder Cancer across 23 companies.

There are 58 clinical trials targeting Bladder Cancer tracked by BioSniper.

The estimated prevalence of Bladder Cancer is approximately 61.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.